We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy Walgreens Boots (WBA) Ahead of Earnings?
Read MoreHide Full Article
Walgreens Boots Alliance, Inc. (WBA - Free Report) has been gaining investor confidence on consistently positive results. The stock has lost 19.4% over a year, versus the broader industry’s 22.8% fall.
Ahead of its second-quarter fiscal 2018 earnings scheduled on Mar 28, we note that the company currently has a market cap of $69.68 billion. Its five-year historical growth rate is also favorable at 12.5% compared with the industry’s 4.3%.
Considering the solid prospects, this Zacks Rank #2 (Buy) stock is an attractive bet for investors at the moment.
The company’s estimate revision trend for the current year has been positive. In the last 60 days, three analysts revised their estimates upward, with no movement in the opposite direction. The estimate revision for earnings increased around 1.2% to $5.79 per share.
Per our Style Score, Walgreens Boots sports a Growth Score of B, which is reflective of the company’s solid prospects.
Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best upside potential.
In this regard, Walgreens Boots has a favorable Net Margin (Net Income/Sales) of 3.2% compared with the industry’s 0.4%. Moreover, the projected sales growth rate of 9.4% surpassed the industry’s rate of 4.5%.
Factors in Favor
Let’s take a look at the possible growth propellers:
Solid Q1 Performance
Walgreens Boots exited the first quarter on a promising note with better-than-expected earnings and revenues. We are also encouraged by the uptick in sales at the Retail Pharmacy International segment. Moreover, Walgreens Boots has been gaining on strategic tie-ups, which brought more patients to its U.S. pharmacies.
Strong Retail Pharmacy USA Business
Over the recent past, we have observed Walgreens Boots’ Retail Pharmacy USA division witnessing comparable prescription growth and benefitting from strength in retail prescription market. Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume owing to previously announced pharmacy partnerships have been driving growth in this space.
Moreover, rising expenditure on prescription drugs and growing demand for specialty drugs have been boosting the retail pharmacy market.
Express Scripts Deal Prospects Promising
We are encouraged by Walgreens Boots’ plans to expand its existing group purchasing efforts with Express Scripts Holding Company to ensure availability of specialty brand drugs. Since biosimilars have the potential to lower production costs, the move is considered a prudent and timely one.
Guangzhou Pharmaceuticals Investment Strategic
We are upbeat about the company expanding its global footprint with its decision to acquire a 40% stake in Sinopharm Holding Guoda Drugstores Co., Ltd. (GuoDa), a subsidiary of China National Accord Medicines Corporation Ltd. On completion, this investment should provide a strong impetus to Walgreens Boots’ worldwide retail pharmacy business. Notably, Shanghai-based GuoDa is a large national pharmacy chain in China. It is the retail pharmacy platform of China National Pharmaceutical Group Corporation (“CNPGC”).
Moreover, the company’s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Should You Buy Walgreens Boots (WBA) Ahead of Earnings?
Walgreens Boots Alliance, Inc. (WBA - Free Report) has been gaining investor confidence on consistently positive results. The stock has lost 19.4% over a year, versus the broader industry’s 22.8% fall.
Ahead of its second-quarter fiscal 2018 earnings scheduled on Mar 28, we note that the company currently has a market cap of $69.68 billion. Its five-year historical growth rate is also favorable at 12.5% compared with the industry’s 4.3%.
Considering the solid prospects, this Zacks Rank #2 (Buy) stock is an attractive bet for investors at the moment.
The company’s estimate revision trend for the current year has been positive. In the last 60 days, three analysts revised their estimates upward, with no movement in the opposite direction. The estimate revision for earnings increased around 1.2% to $5.79 per share.
Per our Style Score, Walgreens Boots sports a Growth Score of B, which is reflective of the company’s solid prospects.
Our research shows that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best upside potential.
In this regard, Walgreens Boots has a favorable Net Margin (Net Income/Sales) of 3.2% compared with the industry’s 0.4%. Moreover, the projected sales growth rate of 9.4% surpassed the industry’s rate of 4.5%.
Factors in Favor
Let’s take a look at the possible growth propellers:
Solid Q1 Performance
Walgreens Boots exited the first quarter on a promising note with better-than-expected earnings and revenues. We are also encouraged by the uptick in sales at the Retail Pharmacy International segment. Moreover, Walgreens Boots has been gaining on strategic tie-ups, which brought more patients to its U.S. pharmacies.
Strong Retail Pharmacy USA Business
Over the recent past, we have observed Walgreens Boots’ Retail Pharmacy USA division witnessing comparable prescription growth and benefitting from strength in retail prescription market. Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume owing to previously announced pharmacy partnerships have been driving growth in this space.
Moreover, rising expenditure on prescription drugs and growing demand for specialty drugs have been boosting the retail pharmacy market.
Express Scripts Deal Prospects Promising
We are encouraged by Walgreens Boots’ plans to expand its existing group purchasing efforts with Express Scripts Holding Company to ensure availability of specialty brand drugs. Since biosimilars have the potential to lower production costs, the move is considered a prudent and timely one.
Guangzhou Pharmaceuticals Investment Strategic
We are upbeat about the company expanding its global footprint with its decision to acquire a 40% stake in Sinopharm Holding Guoda Drugstores Co., Ltd. (GuoDa), a subsidiary of China National Accord Medicines Corporation Ltd. On completion, this investment should provide a strong impetus to Walgreens Boots’ worldwide retail pharmacy business. Notably, Shanghai-based GuoDa is a large national pharmacy chain in China. It is the retail pharmacy platform of China National Pharmaceutical Group Corporation (“CNPGC”).
Moreover, the company’s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) and athenahealth, Inc. .
Bio-Rad Laboratories sports a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>